RxDoctor Payments Data

Ivan Montalvo Otano, MD

Pain Medicine · Watertown, NYNPI 1184660789

Payments from drug & device makers

$3,157in general payments, 2019–2025

Across 97 payments — averaging $32.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertos Medical, Inc.$978
  • Boston Scientific$573
  • MML US, Inc.$372
  • Abbott$263
  • Saluda Medical Americas, Inc.$249
  • Nevro Corp.$135
  • plus $587 from 17 others

What the payments were for

  • Travel & lodging$1,23439%
  • Food & beverage$1,85459%
  • Education$692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,157 in reported general payments places this provider in the 60th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$26,146
Medicare patients
119
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate16$14,260
BelbucaBuprenorphine Hcl20$10,019
MovantikNaloxegol Oxalate12$4,853
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen212$4,661
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen124$1,934
Oxycodone Hcl132$1,793
Fentanyl17$1,742
Buprenorphine13$1,579
Pregabalin75$1,291
Gabapentin109$1,256
Tizanidine Hcl153$1,048
Morphine Sulfate20$679
Duloxetine Hcl42$605
Tramadol Hcl74$570
Morphine Sulfate ErMorphine Sulfate27$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$87$24,27936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 503 pain medicine providers in New York.

Other pain medicine in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →